- Home
- SNT vs ACOG Comparison
SNT vs ACOG Comparison
Compare SNT & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- ACOG
- Stock Information
- Founded
- SNT 1965
- ACOG 2000
- Country
- SNT Canada
- ACOG Canada
- Employees
- SNT N/A
- ACOG N/A
- Industry
- SNT Telecommunications Equipment
- ACOG
- Sector
- SNT Telecommunications
- ACOG
- Exchange
- SNT Nasdaq
- ACOG Nasdaq
- Market Cap
- SNT 95.2M
- ACOG 80.3M
- IPO Year
- SNT 1993
- ACOG N/A
- Fundamental
- Price
- SNT $4.42
- ACOG $9.73
- Analyst Decision
- SNT
- ACOG Strong Buy
- Analyst Count
- SNT 0
- ACOG 1
- Target Price
- SNT N/A
- ACOG $20.00
- AVG Volume (30 Days)
- SNT 52.9K
- ACOG 81.7K
- Earning Date
- SNT 08-25-2025
- ACOG 08-14-2025
- Dividend Yield
- SNT N/A
- ACOG N/A
- EPS Growth
- SNT N/A
- ACOG N/A
- EPS
- SNT 0.22
- ACOG N/A
- Revenue
- SNT $38,038,000.00
- ACOG $4,586,341.00
- Revenue This Year
- SNT N/A
- ACOG N/A
- Revenue Next Year
- SNT N/A
- ACOG $149.89
- P/E Ratio
- SNT $19.64
- ACOG N/A
- Revenue Growth
- SNT 12.79
- ACOG N/A
- 52 Week Low
- SNT $1.40
- ACOG $3.75
- 52 Week High
- SNT $5.04
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- SNT 51.08
- ACOG 61.91
- Support Level
- SNT $4.25
- ACOG $8.01
- Resistance Level
- SNT $4.54
- ACOG $8.34
- Average True Range (ATR)
- SNT 0.24
- ACOG 0.48
- MACD
- SNT -0.00
- ACOG 0.21
- Stochastic Oscillator
- SNT 37.65
- ACOG 94.62
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.